Benutzer: Gast  Login
Titel:

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial.

Dokumenttyp:
Article; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
Autor(en):
Palace, Jacqueline; Wingerchuk, Dean M; Fujihara, Kazuo; Berthele, Achim; Oreja-Guevara, Celia; Kim, Ho Jin; Nakashima, Ichiro; Levy, Michael; Terzi, Murat; Totolyan, Natalia; Viswanathan, Shanthi; Wang, Kai-Chen; Pace, Amy; Yountz, Marcus; Miller, Larisa; Armstrong, Róisín; Pittock, Sean
Abstract:
BACKGROUND: Antibodies to the aquaporin-4 (AQP4) water channel in neuromyelitis optica spectrum disorder (NMOSD) are reported to trigger the complement cascade, which is implicated in astrocyte damage and subsequent neuronal injury. The PREVENT study demonstrated that the terminal complement inhibitor eculizumab reduces adjudicated relapse risk in patients with anti-AQP4 immunoglobulin G-positive (AQP4+) NMOSD. The objective of this analysis was to evaluate the efficacy of eculizumab in reducing...     »
Zeitschriftentitel:
Mult Scler Relat Disord
Jahr:
2021
Band / Volume:
47
Volltext / DOI:
doi:10.1016/j.msard.2020.102641
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/33310418
Print-ISSN:
2211-0348
TUM Einrichtung:
Neurologische Klinik und Poliklinik
 BibTeX